 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

60 Degrees Pharmaceuticals withdraws ACLR8-LR IND application

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use...

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Management investor presentation webcast available Monday 9/11, 7:00 AM ETAttendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE...

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP  Get Free Report) fell 4.1% during mid-day trading on Tuesday . The stock traded as low as $1.32 and last traded at $1.35. 46,135 shares were...

60 Degrees Pharmaceuticals (NASDAQ:SXTP)  Shares Down 4.1%

MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company , GTG ), a global leader in guideline driven genomics-based tests in health...

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report  on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money...

Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode of action differentiated from standard of care treatment , Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 ...

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in nave individualsTafenoquine kills dormant liver stage of P. vivaxparasite and clears the blood stages of P. falciparum , Aug. 22...

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, has been registered on ClinicalTrials.gov60Ps majority-owned subsidiary, 60P ...

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals USFDA-approved drug for malaria prevention, ARAKODA.Most travelers from Canada and the United States to ...

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

Watchers	902
52-Wk Low	$0.67
52-Wk High	$8.65

Market Cap	$1.76M
Volume (M)	21,259.00
52-Wk High	$8.65
52-Wk Low	$0.67

SXTP 60 Degrees Pharmaceuticals Inc

About

Feed

News

Fundamentals